The Microenvironment in Barrett's Esophagus
(BETRNet2 Trial)
Trial Summary
What is the purpose of this trial?
This study aims to elucidate the relationship between the microbiome, inflammation, and the microenvironment in Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC), with the end goal of developing a non-endoscopic testing strategy based on pathogenic factors to identify patients at highest risk for EAC. To accomplish this the investigators will enroll 100 patients with known BE (50 with dysplasia or EAC) and 50 subjects without BE undergoing upper endoscopy. Prior to endoscopy each subject will undergo three minimally invasive potential screening and surveillance tests: saliva (oral microbiome), breath test (exhaled volatile organic compounds), and tethered capsule sponge sampling (methylated DNA markers). The study will evaluate these novel tests in combination with clinical and anthropometric factors to describe an optimal strategy for BE screening and monitoring.
Research Team
Julian A. Abrams, MD, MS
Principal Investigator
Columbia University
Eligibility Criteria
Inclusion Criteria
Treatment Details
Interventions
- Electronic nose device (Procedure)
- Tethered capsule sponge (Procedure)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Columbia University
Lead Sponsor
Mayo Clinic
Collaborator
University of Pennsylvania
Collaborator